Suppr超能文献

尼日利亚专门治疗机构中拉沙热结局的临床和实验室预测因素:一项回顾性观察性队列研究。

Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.

机构信息

Department of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria; Institute of Lassa fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria; Department of Medicine, Faculty of Clinical Sciences, Ambrose Alli University, Ekpoma, Edo, Nigeria.

Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Maryland, MD, USA.

出版信息

Lancet Infect Dis. 2018 Jun;18(6):684-695. doi: 10.1016/S1473-3099(18)30121-X. Epub 2018 Mar 6.

Abstract

BACKGROUND

Lassa fever is a viral haemorrhagic disease endemic to west Africa. No large-scale studies exist from Nigeria, where the Lassa virus (LASV) is most diverse. LASV diversity, coupled with host genetic and environmental factors, might cause differences in disease pathophysiology. Small-scale studies in Nigeria suggest that acute kidney injury is an important clinical feature and might be a determinant of survival. We aimed to establish the demographic, clinical, and laboratory factors associated with mortality in Nigerian patients with Lassa fever, and hypothesised that LASV was the direct cause of intrinsic renal damage for a subset of the patients with Lassa fever.

METHODS

We did a retrospective, observational cohort study of consecutive patients in Nigeria with Lassa fever, who tested positive for LASV with RT-PCR, and were treated in Irrua Specialist Teaching Hospital. We did univariate and multivariate statistical analyses, including logistic regression, of all demographic, clinical, and laboratory variables available at presentation to identify the factors associated with patient mortality.

FINDINGS

Of 291 patients treated in Irrua Specialist Teaching Hospital between Jan 3, 2011, and Dec 11, 2015, 284 (98%) had known outcomes (died or survived) and seven (2%) were discharged against medical advice. Overall case-fatality rate was 24% (68 of 284 patients), with a 1·4 times increase in mortality risk for each 10 years of age (p=0·00017), reaching 39% (22 of 57) for patients older than 50 years. Of 284 patients, 81 (28%) had acute kidney injury and 104 (37%) had CNS manifestations and thus both were considered important complications of acute Lassa fever in Nigeria. Acute kidney injury was strongly associated with poor outcome (case-fatality rate of 60% [49 of 81 patients]; odds ratio [OR] 15, p<0·00001). Compared with patients without acute kidney injury, those with acute kidney injury had higher incidence of proteinuria (32 [82%] of 39 patients) and haematuria (29 [76%] of 38) and higher mean serum potassium (4·63 [SD 1·04] mmol/L) and lower blood urea nitrogen to creatinine ratio (8·6 for patients without clinical history of fluid loss), suggesting intrinsic renal damage. Normalisation of creatinine concentration was associated with recovery. Elevated serum creatinine (OR 1·3; p=0·046), aspartate aminotransferase (OR 1·5; p=0·075), and potassium (OR 3·6; p=0·0024) were independent predictors of death.

INTERPRETATION

Our study presents detailed clinical and laboratory data for Nigerian patients with Lassa fever and provides strong evidence for intrinsic renal dysfunction in acute Lassa fever. Early recognition and treatment of acute kidney injury might significantly reduce mortality.

FUNDING

German Research Foundation, German Center for Infection Research, Howard Hughes Medical Institute, US National Institutes of Health, and World Bank.

摘要

背景

拉沙热是一种病毒性出血性疾病,流行于西非。在拉沙病毒(LASV)最多样化的尼日利亚,尚无大规模的研究。LASV 的多样性,加上宿主遗传和环境因素,可能导致疾病病理生理学的差异。尼日利亚的小规模研究表明,急性肾损伤是一个重要的临床特征,可能是生存的决定因素。我们旨在确定与尼日利亚拉沙热患者死亡率相关的人口统计学、临床和实验室因素,并假设 LASV 是拉沙热患者亚组固有肾损伤的直接原因。

方法

我们对 2011 年 1 月 3 日至 2015 年 12 月 11 日在尼日利亚伊鲁阿专科教学医院接受治疗且 LASV 经 RT-PCR 检测呈阳性的连续拉沙热患者进行了回顾性、观察性队列研究。我们进行了单变量和多变量统计分析,包括逻辑回归,分析了所有可用于确定与患者死亡率相关的人口统计学、临床和实验室变量。

结果

在伊鲁阿专科教学医院接受治疗的 291 名患者中,有 284 名(98%)已知结局(死亡或存活),7 名(2%)因医疗建议出院。总病死率为 24%(68/284 名患者),每增加 10 岁,死亡率风险增加 1.4 倍(p=0.00017),50 岁以上患者的死亡率达到 39%(22/57 名)。在 284 名患者中,81 名(28%)有急性肾损伤,104 名(37%)有中枢神经系统表现,因此两者均被认为是尼日利亚急性拉沙热的重要并发症。急性肾损伤与不良预后密切相关(病死率为 60%[81 名患者中的 49 名];比值比[OR]15,p<0.00001)。与无急性肾损伤的患者相比,有急性肾损伤的患者蛋白尿(39 名患者中的 32 名[82%])和血尿(38 名患者中的 29 名[76%])的发生率更高,血清钾(4.63[标准差 1.04]mmol/L)的平均值更高,而血尿素氮与肌酐比值(无液体丢失病史的患者为 8.6)较低,提示固有肾损伤。肌酐浓度的正常化与恢复有关。血清肌酐升高(OR 1.3;p=0.046)、天门冬氨酸氨基转移酶(OR 1.5;p=0.075)和钾(OR 3.6;p=0.0024)是死亡的独立预测因素。

解释

我们的研究为尼日利亚拉沙热患者提供了详细的临床和实验室数据,并为急性拉沙热中的固有肾功能障碍提供了有力证据。早期识别和治疗急性肾损伤可能显著降低死亡率。

资助

德国研究基金会、德国感染研究中心、霍华德休斯医学研究所、美国国立卫生研究院和世界银行。

相似文献

2
Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study.
Lancet Infect Dis. 2021 Jun;21(6):876-886. doi: 10.1016/S1473-3099(20)30737-4. Epub 2021 Jan 20.
3
Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study.
Lancet Glob Health. 2021 Apr;9(4):e469-e478. doi: 10.1016/S2214-109X(20)30518-0.
5
8
Prevention of lassa Fever in Nigeria.
Trans R Soc Trop Med Hyg. 2010 Jan;104(1):51-4. doi: 10.1016/j.trstmh.2009.07.008. Epub 2009 Aug 26.

引用本文的文献

2
Safety Toxicology Study of Reassortant Mopeia-Lassa Vaccine in Guinea Pigs.
Future Pharmacol. 2025 Jun;5(2). doi: 10.3390/futurepharmacol5020026. Epub 2025 May 31.
3
Lassa fever survivors: long-term health effects and chronic sequelae - a scoping review.
BMC Infect Dis. 2025 Jul 1;25(1):823. doi: 10.1186/s12879-025-11262-1.
4
Expansion of myeloid suppressor cells and suppression of Lassa virus-specific T cells during fatal Lassa fever.
PLoS Pathog. 2025 Apr 17;21(4):e1013111. doi: 10.1371/journal.ppat.1013111. eCollection 2025 Apr.
6
Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.
Emerg Infect Dis. 2025 Feb;31(2):9-16. doi: 10.3201/eid3102.240251.
8
Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.
Mil Med Res. 2024 Dec 16;11(1):78. doi: 10.1186/s40779-024-00581-0.
9
Fatal Lassa fever in cynomolgus monkeys is associated with systemic viral dissemination and inflammation.
PLoS Pathog. 2024 Dec 9;20(12):e1012768. doi: 10.1371/journal.ppat.1012768. eCollection 2024 Dec.

本文引用的文献

1
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.
Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.
2
Annual Incidence of Lassa Virus Infection in Southern Mali.
Am J Trop Med Hyg. 2017 Apr;96(4):944-946. doi: 10.4269/ajtmh.16-0821. Epub 2017 Jan 16.
3
Aseptic Meningitis Caused by Lassa Virus: Case Series Report.
Case Rep Neurol Med. 2016;2016:1978461. doi: 10.1155/2016/1978461. Epub 2016 Nov 13.
5
Infection disease surveillance update.
Lancet Infect Dis. 2016 Feb;16(2):157. doi: 10.1016/S1473-3099(16)00023-2. Epub 2016 Jan 26.
6
Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus.
Cell. 2015 Aug 13;162(4):738-50. doi: 10.1016/j.cell.2015.07.020.
7
Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.
Future Virol. 2015 Mar 13;10(3):233-256. doi: 10.2217/fvl.15.1.
8
Empirical studies on usability of mHealth apps: a systematic literature review.
J Med Syst. 2015 Feb;39(2):1. doi: 10.1007/s10916-014-0182-2. Epub 2015 Jan 20.
9
Lassa fever in post-conflict sierra leone.
PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2748. doi: 10.1371/journal.pntd.0002748. eCollection 2014 Mar.
10
Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity.
Antiviral Res. 2013 Oct;100(1):159-89. doi: 10.1016/j.antiviral.2013.07.006. Epub 2013 Jul 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验